First patient has been successfully dosed in a Phase I clinical trial for IBI302, which is a fully human bi-specific antibody-like drug originated at APBio and licensed to Innovent Biologics (HKEX: 01801) for wet AMD (age-related macular degeneration) with world-wide exclusivity.
AP Biosciences has signed an out-licensing agreement with Tasly Biopharmaceuticals for the development of two bi-specific antibodies for immuno-oncology. Additionally, APBio will generate antibodies from its Omni-Mab antibody phage display library on eight targets selected by Tasly.
OBI Pharma has acquired 67% of APBio and become the majority shareholder of the company, who continues supporting the antibody drug development effort at AP Biosciences.
A bridge round of $3M was closed.
AP Biosciences was awarded a phase II SBIR grant for development of a dual functional biologic for anti-inflammation.
AP Biosciences was awarded a phase I SBIR grant for development of a dual functional biologic for anti-inflammation.
AG-67650, a dual-targeting biologic suppressing fibrosis, was licensed to Allgenesis Biotherapeutics.
A proprietary fully-human antibody phage display library, Omni-Mab, was generated in-house and validated against growth factors, membrane-bound receptors and conformational epitopes.
AP Biosciences was established at the Nankang Biotech Incubation Center (NBIC) in Taipei, Taiwan, for development of next generation antibody drugs with innovative mechanisms of action.